ArticleThe Journal of clinical investigation2021
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes.
Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 119 citations in OpenAlex.
- High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.American journal of respiratory and critical care medicine · 2023Trial
- Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.The Journal of infectious diseases · 2023Trial
- Immune Status and SARS-CoV-2 Viral Dynamics.The Journal of infectious diseases · 2023Trial
- Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.Clinical and translational science · 2023Trial
- Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19.EBioMedicine · 2026Article
- Activated immune cells present a lung interstitial-to-airway/alveolar cross-compartment sharing pattern in severe pneumonia.Clinical and translational medicine · 2026Article
- Variant-divergent death: Omicron intensifies bystander T-cell apoptosis via GDF15-BCL2L13.Cell death discovery · 2026Article
- A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines.Nature communications · 2025Article
- Occurrence and clinical correlates of SARS-CoV-2 viremia in two German patient cohorts.Emerging microbes & infections · 2025Article
- Harnessing 2D and 3D human endometrial cell culture models to investigate SARS-CoV-2 infection in early pregnancy.Clinical science (London, England : 1979) · 2025Article
- Neurological, psychological, psychosocial complications of long-COVID and their management.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection.Pathogens & immunity · 2025Article
- Lights and Shadows of Long COVID: Are Latent Infections the Real Hidden Enemy?Journal of clinical medicine · 2024Review
- SARS-CoV-2 RNAemia as a reliable predictor of long-term mortality among older adults hospitalized in pulmonary intermediate care units: a prospective cohort study.Virology journal · 2024Article
- Patient and Immunological Factors Associated With Delayed Clearance of Mucosal Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Symptom Persistence.The Journal of infectious diseases · 2024Article
- The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.International journal of molecular sciences · 2024Review
- Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications.BMC infectious diseases · 2024Article
- Sample-to-Answer Detection of SARS-CoV-2 Viremia Using Thermally Responsive Alkane Partitions.Analytical chemistry · 2024Article
- Clinical features and multiomics profiles indicate coagulation and platelet dysfunction in COVID-19 viral sepsis.iScience · 2024Article
- Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
30 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUNDSARS-CoV-2 plasma viremia has been associated with severe disease and death in COVID-19 in small-scale cohort studies. The mechanisms behind this association remain elusive.METHODSWe evaluated the relationship between SARS-CoV-2 viremia, disease outcome, and inflammatory and proteomic profiles in a cohort of COVID-19 emergency department participants. SARS-CoV-2 viral load was measured using a quantitative reverse transcription PCR-based platform. Proteomic data were generated with Proximity Extension Assay using the Olink platform.RESULTSThis study included 300 participants with nucleic acid test-confirmed COVID-19. Plasma SARS-CoV-2 viremia levels at the time of presentation predicted adverse disease outcomes, with an adjusted OR of 10.6 (95% CI 4.4-25.5, P < 0.001) for severe disease (mechanical ventilation and/or 28-day mortality) and 3.9 (95% CI 1.5-10.1, P = 0.006) for 28-day mortality. Proteomic analyses revealed prominent proteomic pathways associated with SARS-CoV-2 viremia, including upregulation of SARS-CoV-2 entry factors (ACE2, CTSL, FURIN), heightened markers of tissue damage to the lungs, gastrointestinal tract, and endothelium/vasculature, and alterations in coagulation pathways.CONCLUSIONThese results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes.FUNDINGMark and Lisa Schwartz; the National Institutes of Health (U19AI082630); the American Lung Association; the Executive Committee on Research at Massachusetts General Hospital; the Chan Zuckerberg Initiative; Arthur, Sandra, and Sarah Irving for the David P. Ryan, MD, Endowed Chair in Cancer Research; an EMBO Long-Term Fellowship (ALTF 486-2018); a Cancer Research Institute/Bristol Myers Squibb Fellowship (CRI2993); the Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH awards UL1TR001102 and UL1TR002541-01); and by the Harvard University Center for AIDS Research (National Institute of Allergy and Infectious Diseases, 5P30AI060354).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.